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Objective: The aim of this study was to determine the experience of patients with brain tumors 
and their carers across distinct parts of their treatment pathway and identify their views on 
potential service gaps in need of addressing.
Methods: A structured survey was administered at patient workshops across the UK and online 
through a charity newsletter. Answers to closed questions were analyzed using descriptive 
statistics, and open questions were examined using techniques of inductive content analysis.
Results: A total of 136 survey responses were received, representing patients with a variety 
of diagnoses and geographical locations (30 counties). There was a wide range of opinions on 
the provision of current neuro-oncology services. Key themes identified included a perceived 
lack of information provision, a gap in postdischarge psychological and neuropsychological 
supports, and an unmet willingness for involvement in research.
Conclusion: This national survey enhances our knowledge of current patient and carer experi-
ence within neuro-oncology services. A number of areas of unmet clinical need are highlighted 
providing a basis for informing future patient-centered service improvements and research.
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Introduction
The impact of a diagnosis of a brain tumor is significant and can affect the quality of 
life through disease progression and the effects of treatment.1,2 The effects of a brain 
tumor can manifest in many ways, from neurological disability, including motor, 
speech, visual, and cognitive deficits, to financial concerns and uncertainty regarding 
the disease course and eventual outcomes.
Best practice clinical management of brain tumors requires a multidisciplinary 
approach, requiring patients to have multiple consultations with various health care 
professionals throughout the course of their disease.3 It follows that to deliver care to 
meet patient needs adequately requires robust means of evaluating service quality and 
effectiveness. Furthermore, priorities for patients with cancer are tumor-specific,4 with 
each diagnosis having its own needs with regard to the service provided. It is therefore 
important to evaluate patient care with this in mind, as prescription of generic cancer 
service guidelines may not wholly meet the needs of all patients.
Currently, the patient’s perspective and experience of current neuro-oncology ser-
vices spanning their treatment pathway are under-reported in the scientific literature. As 
early as 1995, the Calman–Hine report recommended that services should be patient-
centered with readily available and accessible information.5 This management approach 
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was re-iterated in 2006 in the National Institute for Health and 
Care Excellence (NICE) guidance for “improving outcomes 
for people with brain and other CNS tumors”.6
While restructuring of cancer services has been shown 
to reduce emergency admissions, length of hospital stay, and 
improved survival in brain tumors,7 both national and local 
surveys have identified areas in which patient experience 
could be improved. The Cancer Patient Experience Survey 
national report 2015 (of which CNS tumors represented <1% 
of patients) showed that despite improvements in cancer care 
since the previous report, there remain inconsistencies8; for 
example, information provision varies throughout disease 
course and inpatient care appears to be more positively 
experienced than health services at home. Recent reports on 
the patient’s experience of CNS tumors identified significant 
variability across the services provided and satisfaction with 
these.9–11 In particular, they recognized that patients felt low 
levels of psychological support, rehabilitation, and supportive 
care as well as some patients experienced difficulties with the 
understanding of information provided at diagnosis. These 
findings were confirmed by a local report within the Anglia 
Cancer Network, again highlighting the need for wider sup-
port services.11
Against this background, we conducted a nationwide sur-
vey to explore the experience of patients with brain tumors and 
their carers across distinct parts of their treatment pathway, 
ranging from initial presentation and diagnosis to specialist 
treatment and rehabilitation. Through this approach, we sought 
to 1) systematically identify service needs from a patient 
perspective and 2) evaluate the potential utility of a number 
of proposed quality improvement interventions in this area.
Methods
Questionnaire design and administration
A structured survey questionnaire was developed to address 
distinct aspects of neuro-oncology service provision, in 
line with the study objectives and previous surveys in this 
area9,11 (Supplementary materials A). Individual items were 
determined through an iterative process involving multiple 
stakeholders including neurosurgeons, oncologists, nurse 
specialists, and patient representatives, thus ensuring face 
validity of the survey.
The survey included a section for demographical infor-
mation followed by 32 closed questions about the following 
four relevant domains: 1) initial diagnosis, 2) first special-
ist appointment, 3) on-going care and rehabilitation, and 
4) involvement in research. Each domain was followed 
by an open question to allow participants to comment on 
each dimension of the pathway. Closed questions included 
multiple-choice questions (with only one or more than one 
possible answers), as well as Likert-type scale items where 
participants were asked to rate each part of the pathway, 
including potential improvements that could be made at each 
stage, on a 1–5 scale. The survey could be completed either 
online or in a paper format.
Study sample
A convenience sample of patients with brain tumors, or their 
carers, was used for the study. Participants were recruited in 
the following two ways: 1) patients or carers were invited 
to participate during six workshops with brain tumor 
patients across the UK (carried out in Cambridge, London, 
 Manchester, and Liverpool, attended by 55 patients), where 
they completed the questionnaire in a paper format, and 2) the 
Brain Tumour Charity included an invitation to complete the 
survey online through a link using SurveyMonkey® in their 
newsletter, circulated via their mailing list between July and 
December 2015. When completed by a carer, the survey was 
answered as a surrogate on behalf of the patient.12
Ethical approval
The format and conduct of the survey were approved by the 
review boards of the two participating charities (The Brain 
Tumour Charity, Farnborough, Hampshire, UK, and Brain-
strust, Cowes, Isle of Wight, UK) through which participants 
were recruited. All responses were recorded anonymously, 
and participants were informed that by completing the ques-
tionnaire, they were consenting to participate.
Analysis
Each of the closed questions was examined in isolation to 
assess for trends in answers. As responses to each question 
were not mandatory, nonresponses were acknowledged in 
further analysis. Results are expressed as the absolute number 
of responders and percentage proportion of the entire cohort 
unless stated otherwise. Where appropriate, answers were 
reviewed by the subgroup of tumor type. For responses on 
an ordinal scale (1–5), responses were grouped into positive 
(4–5), negative (1–2), or neutral (3) responses (refer Supple-
mentary materials A for exact response items).
Techniques of inductive content analysis were used to 
examine emerging themes from the qualitative data of the 
four free-text questions.13 Open coding (labeling) was utilized 
to analyze text data, thus allowing categories of data to be 
generated directly from the answers. Once a code had been 
identified, it was used further to code subsequent answers. 
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The categories were grouped into broader concepts to identify 
emerging themes. Analyses were performed independently 
by two investigators, and any divergent opinions were agreed 
by consensus.
Results
Study population
A total of 136 responses to the survey were received, includ-
ing 55 (40%) from the paper-based questionnaire and 81 
(60%) through the online version. Of all questionnaire 
responses, 98 (72%) responses were completed by patients 
themselves, while the remaining 48 (28%) responses were 
completed on behalf of the patient by a carer.
The majority of responders were female (male:female, 
40 [29.4%]:94 [69.1%], two nonresponders), under the age 
of 65 years (122; 92%), and identified as white British (126; 
93%). The three commonest diagnoses were high-grade gli-
oma (HGG) (54; 40%), low-grade glioma (LGG) (31; 23%), 
and meningioma (28; 21%). Two patients were identified 
as having more than one tumor, for example, both an HGG 
and a meningioma, resulting in a total of 137 tumors across 
the 135 patients who responded to the question. There was a 
wide geographical variation in responses received, with Scot-
land (19, 14%), London (17, 13%), Manchester (14, 10%), 
Cambridgeshire (14, 10%), and Liverpool (7, 5%) represent-
ing the largest regions by responder number. A summary of 
sociodemographic data and diagnosis is shown in Table 1.
Presentation and diagnosis
Initial diagnosis
Quantitative data
The first domain of the survey explored the period prior to 
diagnosis, including mode of presentation to the health ser-
vice, presenting symptoms, and their time course. There was a 
wide variation in time from initial diagnosis to questionnaire 
completion, representing patients at different stages within 
the neuro-oncology pathway. A total of 25 (18%) patients had 
been diagnosed within the last year and 39 (29%) patients 
had been diagnosed more than 5 years prior to completing 
the questionnaire (Figure 1A).
The most common pathway to diagnosis was following 
an emergency presentation to hospital (Figure 1B). The 
proportion of patients who presented this way was higher in 
intrinsic tumors, with 28 (52%) of HGG and 15 (48%) of 
LGG presenting by this mechanism (Table 2). Responses in 
other categories consisted most commonly of referrals for 
Table 1 Responders’ (n=136) demographics by gender, age, 
ethnicity, education, and tumor type
 n (%)
gender
Male
Female
no response
40 (30)
94 (69)
2 (1)
Age (years)
<35
35–44
45–54
55–64
65–74
no response
29 (21)
32 (24)
32 (24)
31 (23)
11 (8)
1 (1)
Ethnicity
White British
Asian or Asian British
Black or Black British
Chinese
Others
no response
126 (93)
2 (1)
1 (1)
1 (1)
5 (4)
1 (1)
Level of education
none
GCSE, O-level, or CSE
A-level or equivalent
Vocational
Undergraduate degree
Postgraduate degree
no response
7 (5)
37 (27)
30 (22)
10 (7)
26 (19)
21 (15)
5 (4)
Geographical location
Scotland
london
Manchester
Cambridgeshire
West Midlands
Liverpool
Yorkshire
Hampshire
Essex
Wales
Oxfordshire
Kent
Othersa
no response
19 (14)
17 (13)
14 (10)
14 (10)
7 (5)
7 (5)
6 (4)
5 (4)
4 (3)
3 (2)
3 (2)
3 (2)
25 (18)
9 (7)
Diagnosis
hgg
lgg
Meningioma
Metastatic tumor
Do not know
Others
no response
54 (40)
31 (23)
28 (21)
1 (1)
4 (3)
19 (14)
1 (1)
Note: aRegions with only one or two responders: Bedfordshire, Berkshire, Bristol, 
Cheshire, Derbyshire, Devon, Dorset, Hertfordshire, Isle of Wight, Lancashire, 
Leicestershire, Lincolnshire, Norfolk, Northern Ireland, Northumberland, 
Nottinghamshire, Staffordshire, and Sussex.
Abbreviations: CSE, Certificate of Secondary Education; GCSE, General Certificate 
of Secondary Education; HGG, high-grade glioma; LGG, low-grade glioma.
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imaging from other hospital specialties, including ophthal-
mology and ENT.
There was a variation in the timing from the initial pre-
sentation to a referral for imaging, with 36 (27%) responders 
referred for a scan on their first encounter with the health 
service relating to this condition, 37 (27%) responders for a 
scan within two to three visits, and the remaining 59 (43%) 
responders referred for a scan after three visits or more 
Table 2 Mechanism of initial presentation for each tumor type
Tumor type Presented as emergency Referred by GP for scan Others No response
n (%) n (%) n (%) n (%)
High-grade glioma 28 (52) 14 (26) 9 (17) 3 (6)
Low-grade glioma 15 (48) 7 (23) 9 (29) 0 (0)
Meningioma 9 (32) 7 (25) 10 (36) 2 (7)
Metastases 0 (0) 0 (0) 1 (100) 0 (0)
Do not know 1 (25) 1 (25) 2 (50) 0 (0)
Others 4 (21) 9 (47) 5 (26) 1 (5)
Figure 1 Responses to questions relating to initial diagnosis.
Notes: Questions from survey: (A) When were you first diagnosed with a brain tumor? (B) How were you first diagnosed? (C) How many times did you visit the hospital/
your GP with the above symptoms before being referred for a scan? (D) How long did it take between being referred for a scan and this taking place? (E) Who was your 
diagnosis given by? (F) Where were you informed of your diagnosis?
Emergency
GP
Others
No response
Less than 1 year ago
1–3 years ago
3–5 years ago
5 years or more
No response
Referred on first visit
2–3 visits
4–5 visits
6 or more
Do not remember
N/A (eg incidental)
No response
Within 1 week
1–4 weeks
4–12 weeks
More than 12 weeks
Do not remember
N/A
No response
A
B
C
D
Consultant
Other doctors
GP
Do not remember
No response
E
0% 20% 40% 60% 80% 100%
Specialist clinic
Hospital ward
Emergency department
GP practice
Do not remember
No response
F
( Figure 1C). Overall, scans were reported to occur in a timely 
manner after initial imaging referral. A total of 52 (38%) 
patients received their initial scan within a week and a further 
35 (26%) patients had a scan within 4 weeks (Figure 1D).
Common presenting symptoms that were individually 
present in more than 25% of patients included headache (61, 
45%), poor balance (41, 30%), seizures (40, 29%), and visual 
disturbance (39, 29%). A total of 37 (27%) patients presented 
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with one symptom, 31 (23%) patients presented with two 
symptoms, 18 (13%) patients presented with three symptoms, 
and 46 (34%) patients presented with four or more symptoms. 
Three tumors were also diagnosed incidentally (Figure 2).
Qualitative data
A total of 59 participants answered the open question on the 
events around their initial diagnosis (Supplementary materi-
als B). The following themes emerged from their answers. 
These themes help to contextualize the responses to the 
closed questions above.
Referrals to a specialist are often seen as delayed and 
negative, often due to initial “wrong” diagnosis in primary 
care: in descriptions of their referral process, both via primary 
care and as an emergency, patients describe their referrals 
as a long and delayed process. Often described are first 
symptoms being misinterpreted and diagnosed as stress or 
anxiety. On some occasions, patients were given a diagnosis, 
for example, vertigo, migraine, and diabetes. Comments on 
Figure 2 Number of presenting symptoms of each responder.
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timing of the referral process involved its length including 
descriptions such as “several visits” and timeframes varying 
from weeks to years.
It took 4 months from first onset of symptoms; including 5 
weeks in hospital undergoing tests & investigations. [Sur-
rogate, Male, HGG]
Kept getting sent home despite concerns, vertigo, 
migraine, anxiety. Mum even told gp she was concerned it 
was a brain tumour. Dad cared me upstairs to gp appoint-
ment when my legs gave way. No one listened we were 
fobbed off. [Surrogate, Male, Ependymoma]
To avoid delays, some patients spoke of using private 
health care to achieve faster imaging and diagnosis. In some 
instances, patients believed there was a “reluctance” of the 
health care professional to refer them for further investiga-
tions or to a specialist.
There were some cases that commented on the referral 
process being fast. A few described a positive experience 
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with the referral process, although none of these cases went 
through a primary care route.
I was lucky, I didn’t have a GP so my optician sent me 
straight to hospital, the process would have been much 
slower via a GP. [Patient, Female, Meningioma]
Everything happened very quickly, from collapse and 
visit to A&E sunday, immediate scan, sent to [hospital] 
sunday night + more scans, diagnosed by neurosurgeon 
on Monday, surgery on Wednesday, discharged on Friday. 
[Surrogate, Female, HGG]
Communication of diagnosis is often felt as a negative 
experience by patients or carers
This aspect spanned from the type of health care professional 
providing the diagnosis (not being a specialist or not the pro-
fessional the patient was expecting to provide the diagnosis) 
to the attitude of the health care professional (described as 
uninterested or insensitive on a number of occasions). Mode 
of provision of diagnosis was often viewed as inappropriate; 
examples of this included phone calls or messages or fol-
lowing a long wait in Accident and Emergency late at night. 
Some patients described needing to chase for the outcomes 
of investigations.
Was given the news while still dazed and confused and 
without any close support. The news was delivered fairly 
bluntly by the registrar. [Patient, Male, LGG]
A minority of patients described a positive experience 
with how their diagnosis was communicated. This included 
the speed of the communication of the diagnosis following 
admission, the professional attitude of the professional giv-
ing the diagnosis, and the information given at this stage.
Information provided on diagnosis is often felt as insufficient, 
difficult, or overwhelming by patients or carers 
Numerous comments revealed that information given at 
this time was insufficient or lacking. Other responses 
stated that when information was given, this was felt to be 
overwhelming and comments included not having someone 
to talk to or no support mechanisms being in place follow-
ing diagnosis.
Could have given info to take away as were given nothing 
to read/take home. [Surrogate, Male, HGG]
The dr was very sensitive when giving diagnosis but 
used medical terms not language i could understand. [Sur-
rogate, Female, LGG]
First specialist appointment
Quantitative data
Following the initial diagnostic scan, 110 (81%) patients were 
seen at a specialist clinic within 6 weeks, with nearly half 
(n=54) of these being seen within 1 week. Despite prompt 
scheduling, patients reported that information provided dur-
ing this period was limited. Only 38 (28%) patients responded 
positively, with 57% patients giving neutral (n=13) or nega-
tive (n=47) responses about the information provided prior 
to the appointment (Table 3).
For the majority of patients, the diagnosis was given by 
a consultant (99, 73%) in either a specialist clinic (59, 43%) 
or a hospital ward (42, 31%) (Figure 1E). Most of the people 
responded positively to both how well their symptoms were 
addressed in the initial appointment, with 79 (58%) patients 
giving a positive response, 20 (15%) patients giving a neutral 
response, and the remainder giving a negative response. Fur-
thermore, 88 (65%) patients felt that they were given a good 
Table 3 Satisfaction with different areas of the clinical pathway
Question Positive  
response
Neutral  
response
Negative 
response
Not 
applicable
No  
response
n (%) n (%) n (%) n (%) n (%)
Before seeing a specialist, how well were you updated/kept informed? 38 (28) 17 (13) 60 (44) 14 (10) 7 (5)
At your first appointment, how well were your symptoms addressed? 79 (58) 20 (15) 21 (15) – 16 (12)
At your first appointment, how much opportunity did you get to ask 
questions?
88 (65) 12 (9) 22 (16) – 14 (10)
At the first appointment, how well did you understand the 
information provided?
50 (37) 41 (30) 31 (23) – 14 (10)
At the time of your first appointment, were you provided with details 
of a contact worker? (If yes, how contactable were they?)
31 (23) 7 (5) 17 (13) 67 (49) 14 (10)
How useful did you find the rehabilitation support received? 37 (27) 12 (9) 35 (2) – 52 (38)
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opportunity to ask questions (Figure 1F). However, patients 
were less positive about their understanding of the informa-
tion provided at this stage. A total of 50 (37%) patients gave 
positive responses to this question, 41 (30%) patients gave 
neutral responses, and a further 31 (23%) patients gave 
negative responses.
With regard to further contact opportunities, 67 (49%) 
patients said that they were not given the details of a key 
worker at the time of their initial appointment. Of those who 
were given a key worker (55), 24 patients found them difficult 
to contact (negative or neutral response).
Qualitative data
Mixed views were also reported by 37 responders making 
further comments on the first specialist appointment.
Overall comments regarding the first specialist appoint-
ment were often negative. In the free-text descriptions, this 
negative experience was as a result of professionals’ attitudes, 
insufficient information provision, or a lack of support fol-
lowing the appointment. These results are expanded in the 
following themes that emerged.
Information provided during the first appointment with the 
specialist is often felt as insufficient or challenging by patients 
or carers
This was described as a result of both insufficient informa-
tion and the difficult nature of receiving information at this 
stage. Comments made included those such as words being 
too technical and a lack of time or opportunity to ask the right 
questions. For some, the information was too challenging and 
understanding the information was an issue.
Left my husband and I googling “glioma” and learning 
what it meant through Internet research. Very frightening. 
[Patient, Female, LGG]
Emotional response to diagnosis is often of shock
The most common emotional response was shock. Other 
responses that were mentioned included fear, scare, terror, 
and sadness.
I was not given much information about the tumour or pos-
sible treatments. i was in shock so i don’t know how useful 
it would have been anyway. [Surrogate, Female, LGG]
Patients’ or carers’ views on their interaction with health 
care professionals during the first appointment with the 
specialist vary, for some being negative and for some being 
positive.
Positive experiences involved professionals being sincere 
and sensitive, and being viewed as willing to help and listen-
ing well. Negative experiences were descriptions of being 
rushed, a view the health care professionals were insensitive, 
and a feeling of being confused by the interaction.
Originally seen by ENT consultant who very rudely stated 
I had a glioma and needed to see neurology but gave no 
other explanation. [Patient, Female, LGG]
Neurosurgeon was very informative and sensitive when 
delivering such bad news. [Surrogate, Female, HGG]
Treatment and post-treatment care
Treatment
The majority of responders received some form of treatment, 
with only 13 (five LGG, four meningioma, two HGG, one 
other, and one unknown) being managed with surveillance 
alone. The majority of patients (103; 76%) had undergone 
surgery. Higher numbers of those with HGG received che-
motherapy and radiotherapy.
On-going care and rehabilitation
Quantitative data
Each responder was asked which areas of care they received 
information on following discharge. A total of 78 (57%) 
responders received information on their diagnosis, and 68 
(50%) responders received information on their treatment. 
Information on support groups, financial support, and chari-
ties was less commonly provided (20 [15%], 14 [10%], and 
20 [15%], respectively) (Figure 3).
Following discharge from treatment, a large proportion 
of patients, 52 (38%), felt that they received no additional 
support. Where responders stated that support was provided, 
this was mainly in the form of physiotherapy, 29 (26%), and 
occupational therapy, 24 (22%). Psychological support and 
neuropsychology following treatment were reported only by 
10 (7%) and 14 (10%), respectively.
When asked to report on how useful the support provided 
was, 37 of the 84 (44%) responders found the rehabilita-
tion support they received to be useful, a further 12 (14%) 
responders were neutral regarding their support, and 35 (42%) 
responders responded negatively about the support (Table 3). 
A perceived gap in support provision was most apparent in 
the domains of psychological support and neuropsychology, 
with 53 of the 95 (56%) responders feeling that they would 
have benefited from psychological support and 21 (22%) 
from neuropsychology (Figure 4). Only 33 of the 107 (31%) 
patients received a care plan on discharge from treatment. Of 
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those who did, the majority (29/33) felt that it was suitable 
for their needs (Figure 5A).
Qualitative data
There were a further 23 responders who gave answers to 
open questions regarding on-going care and rehabilitation 
(Supplementary materials B).
Lack of information regarding follow-up services that were 
available
A common description was that information provided to 
the patient was often lacking or insufficient. This included 
comments on the communication of this information to the 
patient. Patients reported feeling the need to contact support 
services directly for the engagement or requirement of the 
patient to find information for themselves. Communication 
and information provision between services was also raised 
as an issue, with this viewed as being a possible limiting 
factor in patients’ follow-up care.
Follow up is very disjointed and requires a lot of input 
from me to coordinate information and specialists. [Patient, 
Female, LGG]
Support services and follow-up were seen as generally lacking
A number of comments referred to specific services they felt 
were not provided, for example psychological services. A lack 
of services was often seen as related to a geographical region, 
such as “nothing in area” and “rural service should have no 
excuse”.
I was discharged with a promise of home visits from physio 
and ot as i am a mum of 2 who was discharged home with 
a severe left sided weakness. It was 7 months before i was 
seen as i was not a priority. [Patient, Female, LGG]
Figure 3 Information provided following discharge from treatment.
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Participation in research and useful areas 
for development
Research
Quantitative data
The majority of patients, 86 (63%), reported that they had 
not been involved in any studies or clinical trials related to 
their diagnosis and 75 (55%) patients reported that they did 
not have research discussed with them at any point during 
their treatment (Figure 5B and C).
Despite this, a large proportion of patients (94, 69%) 
reported that they would be willing to be included in a 
prospective patient register enabling them to be contacted 
about potential research for which they could be eligible for 
(Figure 5D). In line with this, 88 (65%) patients thought that 
a research register informing them about such studies would 
be a useful development (Table 4).
Most patients also responded positively to being 
approached for participation in research. While most were 
Figure 4 Differences in support received and what was felt would be beneficial.
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happy with being contacted for recruitment after being 
provided information about a particular study (81%, 74/91 
responders), a significant number were also happy to be 
contacted by the research team directly about eligible stud-
ies without prior specific consent (75%, 71/94 responders).
Qualitative data
Free-text responses regarding the creation of a patient 
research register were overall positive in line with the above 
findings. A total of 14 further responses were given to this 
question (Supplementary materials B), and a limited number 
of those responding either had been involved in research or 
had it discussed with them.
A research register is described as a needed and an important 
resource
The majority of patients reported that they felt a register 
would be “vital” with a number of patients expressing 
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 surprise that it did not exist already. Many patients thought 
it would be useful to be involved with a register.
I would have found this useful at the time, so I would sup-
port further work on this to help others. [Patient, Male, 
Acoustic Neuroma]
It is something that I would have expected to happen 
and was disappointed that there is not one as yet. [Patient, 
Female, LGG]
Patients or carers realize about the benefits of research  
and of a patient research register for them and  
future patients
A number of benefits were highlighted, including improving 
the quality of research and benefits for both current and future 
patients. Research benefits described included improving 
prognosis, examining the physical and psychological aspects 
of a diagnosis, and investigating the frequency of imaging 
undertaken.
Figure 5 Responses to questions relating to care plans and involvement in research.
Notes: Questions from survey: (A) Following discharge from treatment, did you receive a personalized care plan to suit to your needs? (B) Have you participated in a study 
or clinical trial related to your tumor diagnosis? (C) Was involvement in research discussed with you at any point? (D) Would you be willing to be included in a patient 
register to inform you about future studies you may be eligible for?
No
Yes, but it did not meet my needs
Yes, and it met my needs
No response
Yes
No
No response
At initial appointment
During treatment
No
No response
0% 20% 40% 60% 80% 100%
Yes
No
No response
A
B
C
D
Table 4 Willingness to be involved in research
Question Positive  
response
Neutral  
response
Negative  
response
No  
response
n (%) n (%) n (%) n (%)
How useful would a patient register informing about eligible studies be? 88 (65) 20 (15) 3 (2) 25 (18)
I would consent to being contacted by the research team only after I have received 
information about a study for which I was potentially eligible and agreed to be 
contacted.
74 (54) 12 (9) 5 (4) 45 (33)
I would consent to be contacted by a research team directly if I am potentially 
eligible for a study.
71 (52) 11 (8) 12 (9) 42 (31)
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I understand that I am being monitored long term to keep 
an eye on changes to my condition but in these in between 
periods I would like to know that I am able to engage in 
anyway possible so that others could benefit from my experi-
ence, either with these surveys or being available for clinical 
trials. [Patient, Male, LGG]
Vital not only to improve the poor prognosis for such 
a high percentage of patients with a brain tumour but for 
more research into the physical and psychological effects of 
a diagnosis. [Patient, Female, Haemangioblastoma]
Concerns of patients or carers on the creation of a patient 
research register was related to privacy and quality of the 
information recorded
Patients mentioned the need to consider patients’ privacy and 
the need to clearly specify inclusion criteria for a register, to 
collect all relevant information, and to ensure it is gathered 
from all relevant patients.
My only concerns would be about privacy. [Patient, Male, 
LGG]
Potential areas for quality improvement
A number of potential service improvement interventions 
were put to responders to determine their perceived utility. 
These included the provision of a digital system to enable 
health care professionals to seek specialist neuro-oncology 
input upon initial diagnosis (referral portal), the use of a 
patient-reported questionnaire for monitoring symptoms and 
concerns, and a patient-facing record detailing information 
on their condition and its management.
For the initial diagnosis phase, 107 (79%) reported that 
they thought a referral portal would be useful at the initial 
stage of their care pathway. Most (92, 68%) of them also 
responded positively to the idea of a structured questionnaire, 
to allow the recording of their symptoms and concerns, tak-
ing place at their initial appointment (Table 5). Participants 
were asked the frequency at which they would be willing to 
undertake these. A total of 27 (20%) participants were happy 
to complete these monthly, 39 (29%) participants were happy 
to complete these 3 monthly, and 31 (23%) participants were 
happy to complete these less frequently than 6 monthly. A 
small number of patients (5, 4%) were happy to complete 
these at the time of either a clinic appointment or scan.
A total of 100 (74%) patients felt that a patient informa-
tion record would be useful, reflecting the perceived difficulty 
with information provision and retention. When asked about 
specific content items, over 70% of responders thought that 
each of the following would be a useful component of a 
patient information record: specific information about diag-
nosis and treatment, information about symptoms and side 
effects of treatment, and information about future appoint-
ment and treatment, personalized plan, and key contacts.
Discussion and conclusion
Discussion
We have conducted a UK-wide survey to determine patient 
perspectives on current neuro-oncology service provision 
across key phases of management. The survey was conducted 
through both workshops and online surveys, and within 
the limitations of a self-selecting sample, responses from 
a diverse patient cohort were achieved. We are aware that 
our purposive sample may not have included patients either 
unable or unwilling to attend the workshops or complete 
the online survey. It is therefore possible that certain issues 
related to these populations and their condition may have 
been under-represented, for example, those with significant 
cognitive and physical impairment. Nevertheless, our sample 
included a high proportion of carer responses, which could 
potentially act as surrogates for these patients.12 With the 
exception of an atypical gender ratio (male:female 3:7), other 
parameters (including age and tumor types) were otherwise in 
line with the reported values for patients with brain tumors.8 
We are not aware of any reported gender differences in patient 
views on neuro-oncology care, and there is some evidence 
that gender does not seem to affect patient satisfaction in 
inpatient surgical care.14 We made no presumption of differ-
Table 5 Areas for further development
Question Positive 
response
Neutral 
response
Negative 
response
No 
response
n (%) n (%) n (%) n (%)
How useful would a direct referral portal be in improving time to diagnostic process? 107 (79) 14 (10) 4 (3) 11 (8)
How useful would a structured questionnaire recording your symptoms and concerns 
at your first appointment be?
92 (68) 13 (10) 18 (13) 13 (10)
How useful would a patient information record be? 100 (74) 6 (4) 1 (1) 29 (21)
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ences in care requirements by tumor type as we set out to 
explore common issues across key phases of neuro-oncology 
care. The comprehensive nature of the survey across all tumor 
types and geographical locations enhances our knowledge 
of the current patient experience throughout their journey of 
the neuro-oncology service. It offers a unique perspective on 
practice implications by detailing patient views to potential 
service interventions and provides a platform for further 
disease-specific studies in this area.
The qualitative data included provided us with rich 
information about patient perceptions on their care. While 
much of this data confirmed the quantitative data from the 
survey, it allows contextualization of these results and further 
exploration of relationships impacting patient experience. 
While patient recall is likely to imperfect, given nearly one-
third of responders were diagnosed 5 years or more ago, the 
findings are broadly in line with previous reports in this area. 
Combining both closed and open questions, alongside vary-
ing methods of survey completion, gives a more complete 
view of patient opinions.15
Despite a number of national surveys across cancer ser-
vices demonstrating wide variations in care,8,9 there is little 
formally published literature on the subject within neuro-
oncology. Outside of surveys, a previous study exploring 
patient views on general cancer care quality in a single region 
has reported considerable variation in service satisfaction 
despite an overall high baseline.16 Other studies investigating 
cancer patient experience demonstrated that similar issues 
shaped patients’ experience across tumor types, although 
these translated into different service improvement priorities 
for each tumor.4 This highlights the need for tumor-specific 
studies.
Our results highlight a number of issues in the provision 
of care for patients with brain tumors. The high proportion 
of emergency presentations and multiple visits to health 
care services has been reported in epidemiological stud-
ies.17,18 This raises a number of issues; a number of patients 
deteriorate while waiting for clinical input and emergency 
presentations are associated with a lower 1-year survival,17,18 
although at times emergency presentation is clearly unavoid-
able (eg, presentation with a first seizure). Improving time 
to diagnosis through evidence-based guidance for clinicians 
and public awareness may lessen the devastating impact that 
diagnosis of a brain tumor has on patients.19
While the process from referral to scan and subsequent 
initial visit was reported to happen in a timely manner, 
provision of information at this stage was felt to be limited. 
 Concern was raised over information available prior to the 
scan and the understanding of the information provided 
prior to the initial visit at a neuroscience center. Information 
provision was also an issue following discharge, although 
some areas were covered well (information on diagnosis 
and treatment).
It is recognized that information provision throughout 
a cancer diagnosis can represent a logistical challenge and 
may arise as a result of the disease process itself.20 Previous 
suggestions to address this include patient-centered service 
organization and integration early in cancer care.21
We also found a mismatch between patient expectations of 
support following treatment and what was provided according 
to the responders. Perceived support was especially lacking 
in psychological and neuropsychology domains, in line with 
previous reports on brain tumor patients.20,22,23 It can be dif-
ficult to assess the care needs of cancer patients and a lack of 
concordance exists between function, symptoms, and needs, 
especially in those who are low functioning.24
Despite the reported gap in further support, there are lim-
ited recommendations on how this can be addressed. Previous 
reports have suggested the introduction of objective neuro-
psychology25 and quality-of-life assessments throughout the 
patient’s journey26 as a mean of identifying potential issues 
early on and allowing intervention to establish support and 
coping mechanisms. Capturing quality-of-life data as a part of 
routine clinical care also provides an opportunity to develop 
research themes to improve the understanding of presenting 
symptoms and presentation mechanisms to facilitate more 
timely imaging and diagnosis and potentially to improve the 
survival and quality of life for brain tumor patients.18 Our 
results also suggest that patients would respond positively 
to the introduction of a referral portal, structured question-
naire at the initial appointment, and an information record 
as a practical mean of addressing existing gaps. These issues 
have also been raised through national initiatives, including 
four “calls to action” around getting a diagnosis, accessing 
treatment and services, improving people’s quality of life, 
and receiving wider support services.9
The majority of patients and carers undertaking this 
survey showed an interest in on-going research and would 
be supportive of being included in a prospective research 
register. Inclusion of patient experience is crucial in both 
service improvement and on-going clinical trials.27 In other 
areas of research, for example, dementia, development of 
a research registry and networks has already been success-
fully implemented.28 These interventions have been shown 
to enhance research delivery within England and have led 
to a 600% increase in the number of people taking part in 
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research studies.29 While the majority of patients in our cohort 
were not approached for participation in research, it is likely 
that a lack of clinical trials for which they are eligible may 
also have been a contributory factor. It follows therefore that 
the establishment of more clinical trials with broader inclu-
sion criteria will be necessary in order for efforts aimed at 
increasing research participation, such as a patient register, 
to become effective.
Conclusion and implications for practice
This UK-based survey demonstrates significant variation in 
satisfaction with various aspects of neuro-oncology services. 
We have identified three potential key areas of improvement 
in current neuro-oncology services:
•	 Information provision,
•	 Access to support services,
•	 Inclusion in research.
These findings provide useful insight into potential qual-
ity improvement measures that can positively impact neuro-
oncology services and are in line with other published studies 
reporting both the utility and effectiveness of such interven-
tions.30–32 There is urgency in taking such potential initiatives 
forward, given that the delay in diagnosis of brain tumor is 
a common cause of medicolegal complaints and litigation.33
Potential measures to consider for addressing these gaps 
include
1. Establishment of a more streamlined and timely referral 
process through digital means that enables more interac-
tive communication between different providers.34
2. Enhancing initial and follow-up assessments with 
routine quality-of-life measurement and health needs 
assessment.35
3. Implementation of a patient-accessible portal providing 
tailored information resources and appropriate portions 
of the patient medical record.36
4. Creation of a comprehensive register to prospectively 
engage willing patients and carers in future relevant 
research.28
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